Antimicrobials' non-antimicrobial anti-inflammatory action — NF-κB·MMP and other pleiotropic mechanisms
Several antimicrobials (antibiotics·antifungals), independent of their antimicrobial action, directly suppress host inflammatory signaling (NF-κB·MMP·cytokines·neutrophils·iNOS, etc.). A pharmacologic rationale for "targeted clearance → resolution of chronic downstream symptoms."A mechanistic/literature summary — not a treatment protocol and no guarantee of efficacy.
Cross-cutting targets
What they aim at
Sub-antimicrobial-dose doxycycline (SDD) — even at doses with no antibacterial activity, the MMP/anti-inflammatory action alone is effective (periodontitis Periostat 20 mg, rosacea Oracea 40 mg, both FDA-approved). The decisive example that the two actions can be separated.
Mechanisms by class
Classes with an anti-inflammatory axis
- NF-κB·ERK1/2 inhibition — clarithromycin binds
NIPSNAP1/2, blocking NF-κB-mediated IL-8 induction on TLR4 stimulation. Cytokine modulation via mitochondrial quality control. - Cytokines: IL-1·IL-6·IL-8·TNF-α ↓ / GM-CSF·CCL2·sE-selectin ↓
- Neutrophils: chemotaxis·infiltration ↓, superoxide ↓, LTB4 formation ↓, adhesion-molecule blockade, mucus ↓
- Clinical: low-dose long-term anti-inflammatory therapy in DPB·COPD·asthma·CF (distinct from the antimicrobial effect)
Ref: CMR 2010 · 15586558 · 19633061 · NIPSNAP1/2
- The archetypal MMP inhibitor — inhibits both synthesis and activity of MMP-8·MMP-9. Mechanism: active-site Zn²⁺·Ca²⁺ chelation (direct) + gene-expression suppression.
- NF-κB downregulation → TNF-α·IL-6·IL-1β ↓
- iNOS: dose-dependent suppression at the expression level of mRNA·protein (not direct enzyme inhibition)
- minocycline: MMP + microglia inhibition + p38 MAPK·PI3K/Akt modulation, IL-10 ↑, iNOS·MMP inhibition (colitis), CNS penetration
Ref: PNAS 1996 · SDD 15088884 · PMC3471324 · minocycline colitis
- Anti-inflammatory: macrophage TNF-α·IL-1β ↓, serum TNF-α ↓ in LPS mice
- Mechanism: inhibition of TLR4/MD2/LPS complex·receptor dimerization·NF-κB nuclear translocation. PDE inhibition; AP-1·NFAT·NF-IL6·NF-κB suppression. The keto-carbonyl's Mg²⁺ binding is key.
- ⚠️ Dual-edged: tendinopathy (MMP↑·collagen damage in tendon)·mitochondrial toxicity — hard to view as a pure anti-inflammatory
- Different in kind: not NF-κB anti-inflammation but an anti-angiogenic·anti-Hedgehog axis
- ① anti-Hedgehog (Gli1·Ptch1·SMO inhibition) ② inhibition of VEGFR2 glycosylation·trafficking·signaling ③ AKT/mTOR inhibition (+ P-gp reversal)
- From the inflammation angle: inhibiting angiogenesis·endothelial proliferation = blocking the vascular component of chronic inflammation
Ref: Non-fungal cutaneous disease review · VEGFR2 (Cancer Res 2011) · ACS Chem Biol
- Squalene-epoxidase inhibitor class. Independent of antifungal action, reported anti-inflammatory + antioxidant (free-radical scavenging)
- Allylamines (including naftifine) inhibit neutrophil chemotaxis·reactive oxygen·LTB4 (5-LOX pathway) → improve inflammatory tinea·seborrheic dermatitis
- ⚠️ NF-κB·MMP mechanisms are not as precisely characterized as for macrolides/tetracyclines (overview level)
- Anti-inflammatory via modulation of neutrophil function (rosacea·acne). The antioxidant effect is via neutrophil cell function, not direct ROS scavenging. Suppresses cell-mediated immunity·chemotaxis
- Clinical: topical for rosacea; Crohn's·periodontitis (dual anaerobe + anti-inflammatory)
Ref: BJD 1986 (2936372) · neutrophil free-radical inhibition
- Gut-selective PXR (pregnane-X-receptor) activation → NF-κB inhibition → gut inflammatory mediators ↓. Serum IL-1β·IL-6·TNF-α ↓
- Microbiota modulation + reduced bacterial translocation + direct anti-inflammatory. Nonabsorbed → few systemic effects
- Clinical: standard in IBS·IBD·hepatic encephalopathy·SIBO. The exemplar of "clearance + anti-inflammatory + barrier"
- Inhibits neutrophil recruitment·NF-κB activity·TNF-α production. Suppresses exotoxin·superantigen production in toxic shock (via protein-synthesis inhibition). Anti-inflammatory in acne
- sulfasalazine / 5-ASA: NF-κB inhibition (IBD·RA DMARD)
- dapsone: potent neutrophilic anti-inflammatory (MPO·reactive-oxygen inhibition)
- hydroxychloroquine / chloroquine: inhibits TLR signaling·lysosome·antigen presentation (lupus·RA DMARD)
- nitazoxanide: NF-κB inhibition·anti-inflammatory (gut). polymyxin/colistin: direct LPS binding·neutralization (toxin neutralization, not clearance). rifampin: some immunomodulation
- Same-class extensions: azithromycin·roxithromycin·erythromycin; tetracycline derivative tigecycline. nystatin (gut-topical, weak anti-inflammatory). Quorum-sensing·biofilm inhibition → indirectly reduces virulence·inflammatory stimulus
Summary matrix
Drug × mechanism
| Drug | NF-κB | MMP | iNOS | Cytokines | Neutrophil/ROS | Notable |
|---|---|---|---|---|---|---|
| macrolide | ✓ | · | · | ✓✓ | ✓✓ | ERK1/2·NIPSNAP |
| doxycycline (SDD) | ✓ | ✓✓ | ✓ | ✓ | · | Zn-chelation + expression |
| minocycline | ✓ | ✓ | ✓ | ✓✓ | ✓ | microglia·CNS·IL-10↑ |
| ciprofloxacin | ✓ | ⚠︎↑ | · | ✓ | · | TLR4·PDE — dual-edged |
| itraconazole | (limited) | · | · | · | · | Hedgehog·VEGFR2·mTOR |
| terbinafine | · | · | · | · | ✓ (LTB4) | allylamine · overview-level |
| metronidazole | · | · | · | · | ✓ | neutrophil function |
| rifaximin | ✓ (PXR) | · | · | ✓ | · | gut-selective·nonabsorbed·SIBO |
| clindamycin | ✓ | · | · | ✓ | ✓ | toxin production ↓ |
| sulfasalazine | ✓ | · | · | ✓ | · | IBD·RA DMARD |
| dapsone | · | · | · | · | ✓✓ | neutrophil (MPO·ROS) |
| hydroxychloroquine | (TLR) | · | · | ✓ | · | lysosome·antigen presentation |
| polymyxin/colistin | · | · | · | ✓ | · | direct LPS neutralization |
| β-lactam·aminoglycoside | · | · | · | ⚠︎↑ | ⚠︎↑ | bacteriolysis → endotoxin·Herxheimer |
✓✓ strong/core · ✓ present · · no clear/weak evidence · (…) indirect/limited · ⚠︎↑ increases instead
Caution
No anti-inflammatory / rather pro-inflammatory
⚠️ Not every antibiotic is anti-inflammatory
β-lactams (penicillins·cephalosporins)·aminoglycosides·vancomycin: no clear anti-inflammatory action. On the contrary, bacteriolysis releases cell-wall·endotoxin (LPS·peptidoglycan), spiking cytokines → Jarisch–Herxheimer reaction (transient worsening early in clearance).
An exceptional non-antibiotic effect: ceftriaxone upregulates the glutamate transporter (GLT-1) → neuroprotection (ALS studies). A distinct action rather than anti-inflammatory.
Link to the clinical frame
Targeted clearance → loss of downstream inflammation
The observation that "after clearance, chronic downstream symptoms (pain·skin·gut) improve together" may be the joint effect of a reduced bacterial/fungal load plus these drugs' direct anti-inflammatory action (downregulating NF-κB·MMP·cytokines·neutrophils). In particular, sub-antimicrobial-dose doxycycline working without any antibacterial activity supports that the two actions are separable.
The drug choice itself governs downstream inflammation. Concurrent downstream improvement is seen more when using classes with an anti-inflammatory axis (macrolides·tetracyclines·clindamycin·rifaximin, etc.), whereas β-lactams·aminoglycosides can instead cause early worsening (Herxheimer).
This is a mechanistic/literature summary (for education·research), not a treatment protocol or guarantee of efficacy. Actual agent·dose·duration are individual clinical decisions. When moved to public content, medical-advertising guardrails apply (no efficacy guarantees, no patient testimonials).
References
References
Macrolides
Clinical implications of the immunomodulatory effects of macrolides (PubMed 15586558). · NIPSNAP1/2 · mitochondrial quality control (PMC10824736).
Tetracyclines
Tetracyclines inhibit iNOS — a novel mechanism. PNAS 1996. · Sub-antimicrobial doxycycline as MMP inhibitor (15088884).
Non-antibacterial tetracycline formulations (PMC3471324). · Minocycline attenuates colitis via iNOS/MMP.
Fluoroquinolones · Azoles · Allylamine
Immunomodulatory activities of fluoroquinolones (16518713). · Cipro/Levo · TLR4/NF-κB (PMC6637517).
Itraconazole inhibits angiogenesis (VEGFR2). Cancer Res 2011. · Itraconazole in nonfungal cutaneous diseases. · Terbinafine overview.
Metronidazole · Rifaximin · Clindamycin · Sulfones
Anti-oxidant action of metronidazole (BJD 1986). · Rifaximin · PXR/NF-κB (PMC9656351).
Clindamycin derivative · NF-κB/TNF-α/neutrophil. · Dapsone in dermatology. · HCQ · sulfasalazine (RA).
Disclaimer. Educational/literature summary for healthcare professionals. It guarantees no specific outcome or cure and is not a treatment protocol. Agent·dose·duration·interactions·safety follow individual clinical judgment and current evidence. Citations are representative and do not substitute for the full body of evidence.
© 2026 Neo-Skepticism · June-sang Yang, MD · Clinician deep-dive — NF-κB · MMP · iNOS · neutrophil · PXR · VEGFR2